{
    "symbol": "EW",
    "quarter": 1,
    "year": 2022,
    "date": "2022-04-26 20:09:07",
    "content": " Although we haven't fully overcome the January Omicron impact, we are maintaining all of our previous full year sales guidance ranges for 2022, despite more pronounced foreign exchange headwinds and COVID-related hospital staffing challenges in the U.S. As a reminder, for total Edwards, we expect sales of $5.5 billion to $6 billion; for TAVR $3.7 billion to $4.0 billion; for TMTT $140 million to $170 million; for Surgical Structural Heart $870 million to $950 million; and for Critical Care $820 million to $900 million."
}